AU729869B2 - Integrin antagonists - Google Patents

Description

Title of the Invention Integrin antagonists Field of the Invention The present invention provides novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor ligands. More particularly, the compounds of the present invention are avp3 antagonists, avp5 antagonists or dual avp3/avp5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

1o Background of the invention This invention relates to compounds for inhibiting bone resorption that is mediated by the action of a class of cells known as osteoclasts.

Osteoclasts are multinucleated cells of up to 400pim in diameter that resorb mineralised tissue, chiefly calcium carbonate and calcium phosphate, in vertebrates. They are actively motile cells that 15 migrate along the surface of bone. They can bind to bone, secrete necessary acids and proteases and thereby cause the actual resorption of mineralised tissue from the bone.

More specifically, osteoclasts are believed to exist in at least two physiological states. In the secretory state, osteoclasts are flat, attach to the bone matrix via a tight attachment zone (sealing zone), become highly polarised, form a ruffled border, and secrete lysosomal enzymes and protons to resorb bone. The adhesion of osteoclasts to bone surfaces is an important initial step in bone resorption. In the migratory or motile state, the osteoclasts migrate across bone matrix and do not take part in resorption until they attach again to bone.

(R:\LIBC]06820.doc: bay WO 98/31359 PCT/US98/00617 Integrins are transmembrane, heterodimeric, glycoproteins which interact with extracellular matrix and are involved in osteoclast attachment, activation and migration. The most abundant integrin in osteoclasts (rat, chicken, mouse and human) is the vitronectin receptor, or avP3, thought to interact in bone with matrix proteins that contain the RGD sequence. Antibodies to avp3 block bone resorption in vitro indicating that this integrin plays a key role in the resorptive process. There is increasing evidence to suggest that avp3 ligands can be used effectively to inhibit osteoclast mediated bone resoption in vivo in mammals.

The current major bone diseases of public concern are osteoporosis, hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilizationinduced osteopenia, and glucocorticoid treatment.

All these conditions are characterized by bone loss, resulting from an imbalance between bone resorption (breakdown) and bone formation, which continues throughout life at the rate of about 14% per year on the average. However, the rate of bone turnover differs from site to site, for example, it is higher in the trabecular bone of the vertebrae and the alveolar bone in the jaws than in the cortices of the long bones. The potential for bone loss is directly related to turnover and can amount to over 5% per year in vertebrae immediately following menopause, a condition which leads to increased fracture risk.

There are currently 20 million people with detectable fractures of the vertebrae due to osteoporosis in the United States. In addition, there are 250,000 hip fractures per year attributed to osteoporosis. This clinical situation is associated with a 12% mortality rate within the first two years, while 30% of the patients require nursing home care after the fracture.

Individuals suffering from all the conditions listed above would benefit from treatment with agents which inhibit bone resorption.

Additionally, avp3 ligands have been found to be useful in treating and/or inhibiting restenosis (recurrence of stenosis after corrective surgery on the heart valve), atherosclerosis, diabetic -2- WO 98/31359 PCT/US98/00617 retinopathy, macular degeneration and angiogenesis (formation of new blood vessels), and inhibiting viral disease. Moreover, it has been postulated that the growth of tumors depends on an adequate blood supply, which in turn is dependent on the growth of new vessels into the tumor; thus, inhibition of angiogenesis can cause tumor regression in animal models. (See, Harrison's Principles of Internal Medicine, 12th ed., 1991). avp3 antagonists, which inhibit angiogenesis, are therefore useful in the treatment of cancer for inhibiting tumor growth. (See e.g., Brooks et al., Cell, 79:1157-1164 (1994)).

Moreover, compounds of this invention can also inhibit neovascularization by acting as antagonists of the integrin receptor A monoclonal antibody for avI5 has been shown to inhibit VEGFinduced angiogenesis in rabbit cornea and the chick chorioallantoic membrane model; M.C. Friedlander, et.al., Science 270, 1500-1502, 1995.

Thus, compounds that antagonize avp5 are useful for treating and preventing macular degeneration, diabetic retinopathy, and tumor growth.

In addition, certain compounds of this invention antagonize both the avp3 and avp5 receptors. These compounds, referred to as "dual avp3/avP5 antagonists," are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.

It is an object of the present invention to identify compounds which bind to the avp3 receptor, avp5 receptor or both the avp3 and receptors.

It is a further object of the invention to identify compounds which act as antagonists of the avP3 receptor. It is another object of the invention to identify avp3 antagonist compounds which are useful agents for inhibiting: bone resorption mediated by osteoclast cells, restenosis, atherosclerosis, inflammation, diabetic retinopathy, macular degeneration and angiogenesis in animals, preferably mammals, especially humans. Still another object of the invention is to identify cav3 antagonists which cause tumor regression and/or inhibit tumor growth in animals.

4 A further object of the invention is to identify avp3 antagonists useful for preventing or treating osteoporosis. An additional object of the invention is to identify avp3 antagonists useful for treating cancer.

It has now been found that the compounds of the present invention, avp3 ligands, are useful for inhibiting bone resorption in mammals. Thus, the compounds of the present invention are useful for preventing or reducing the incidence of osteoporosis.

Additionally, the cvp3 ligands of the present invention are also useful for treating and/or inhibiting restenosis, diabetic retinopathy, macular degeneration, viral disease, atherosclerosis and/or angiogenesis in mammals.

o oe [I:\DAYLIB\libaa]8429.doc:kww Pages 5 to 12 This page has intentionally been left blank [I:\DAYLIB\Iibaa]9429.doc~kww 13 Summary of the Invention The present invention provides av133 antagonist compound of the formula A compound of the formula X-Y-Z-Aryl-A-B wherein Aryl is a 6-membered aromatic ring containing 0, 1 or 2 nitrogen atoms wherein Aryl is unsubstituted or substituted with R 8 and R 9 X is selected from 11

-C-NR

2

R

3

-NR

1

-C-NR

3

R

4 a 5- or 6- membered monocyclic aromatic or nonaromatic ring system containing 0, 1 or 2 heteroatoms selected from N, 0 or S wherein the 5- or 6-membered ring system is either unsubstituted or substituted with R' and R3, or a 9- to 14-membered fused polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1, 2 or 3 heteroatoms selected from N, 0 or S, and wherein the polycyclic ring system is either unsubstituted or substituted with R 1 and R 2 Y is selected from the group consisting of

C

0 8 alkylene,

C

3 10 cycloalkyl,

CO..

8 alkylene-NR' 0 -CO-Co..s alkylene,

C

0 8 allcylene-CONR 0

-CO..

8 alkylene,

CO..

8 alkylene-O-CO..

8 alkylene,

C

0 8 alkylene-NR'-CO..s alkylene, 0:

CO.

8 alkylene-S(O) 2

-CO..

8 alkylene,

CO..

8 allcylene-S0 2 -NR' -Co8 alkylene,

CO.

8 alkylene-NR' 0 -S0 2 -CO..s alkylene,

CO..

8 alkylene-CO-CO..s alkylene,

(CH

2 6 ary1(CH 2

(CH

2 )o.6 aryl-CO-(CH 2 )o 4 6, (CH2)o..6 aryl-CO-NH-(CH 2 or

OR,

~T (CHt 2 8

CH(CH

2 0 8 Z and A are each independently selected from [I:\DAYLIB\Iibaa]S429.doc:kww 14

(CH

2

(CH

2 )m..O(CH 2

(CH

2 )mNR 1 1

(CH

2 0 0 0

(CH

2 )mCNRii1 (CH 2 )n,(CH 2 )mNRii1 C(CH 2 )n,(CH 2 )mC(CH 2 )n, S 0 11 1 (0H 2 )mC(CH 2

(CH

2 )mSO 2

(CH

2

(CH

2 )mS(CH 2 )n,

(CH

2 )mSO(CH 2

(CH

2 )mSO 2

NR"

1

(CH

2

(CH

2 )mNR" SO 2

(CH

2

(CH

2 )mCR' 'CR 2

(CH

2 or

(CH

2 )mC-=C.{CH 2 )n, where m and n are each independently an integer from 0 to 4; B is 0 11 13

C-R

R 6 R7 where p is an integer from i to 3; R, ,R R' R8 R9 R ,R and R 1 2 are each independently selected from hydrogen, halogen,

CI-

1 o alkyl, aryl CO..

5 alkyl, amino CO 0 8 alkyl,

C

1 3 acylamino CO..

8 ailkyl,

C

1 6 alkylamino CO.

8 alkyl,

C

1 dialkylamino CO..

8 alkyl, aryl CO..

6 alkylanino C 0 6 ailkyl, CI-4 alcoxyamnino COs8 alkyl, hydroxy C 1 6 alkylamino C 0 8 alkyl, CI-4 alkoxy CO-6~ alkyl, or CI-4 alkoxycarbonyl Co..

6 alkyl; R 6 is selected from hydrogen,

C

1 8 alkyl or aryl CO..

6 alkyl; (I:\DAYLIB\Iibaaj8429.doc:kww

R

7 is selected from

C

7 15 polycyclyl C 0 4 6 alkylsulfonylamino CO 0 6 alkyl or

C

7 15 polycyclyl C 0 6 alkylcarbonylamino C 04 6 alkyl; wherein the polycyclyl may be unsubstituted or substituted with R' 4 R 15, R 16and R1 7 and wherein any of the alkyl groups may be unsubstituted or substituted with R" 4 and R1 5 R 13 is selected from hydroxy,

C

1 8 alkyloxy, aryl. C 04 alkyloxy, CI-8 alkylcarbonyloxy CI-4 alkyloxy, aryl C 1 8 alkylcarbonyloxy C 1A- alkyloxy,

C

1 dialkylamninocarbonylmethyloxy, aryl. C 1 6 dialkylaminocarbonylmethyloxy or an L- or D-ainino acid joined by an amide linkage and wherein the carboxylic acid moiety of said amino acid is as the free acid or is esterified by C 1 6 alkyl; and

R'R

4

R'

5

R

6 and R' are each independently selected from hydrogen, halogen, 20 C 1 1 alkyl, C 3 8 cycloalkyl, oxo, aryl, aryl. C 1 8 ailkyl, amino, amino C 1 8 alkyl, 1 3 acylamino, C 1 3 acylamino C 1 8 alkyl, C 1 6 alkylamino, C 1 6 alkylamino-CI..s alkyl, C 1 6 dialkylainino, C 1 6 dialkylamino C 1 8 ailkyl, CI-4 alkoxy, C14 alkoxy-

C

14 6 alkyl, hydroxycarbonyl, hydroxycarbonyl C 1 6 ailkyl, C 1 3 alkoxycarbonyl,

C

1 3 alkoxycarbonyl C 14 6 alkyl, hydroxycarbonyl-C..

6 alkyloxy, hydroxy, hydroxy CI-6 alkyl, C 1 6 alkyloxy C 14 6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, C 1 8 alkyl-S(O)q, C 1 8 alkylaminocarbonyl, *C 1 8 dialkylaminocarbonyl, 14- alkyloxycarbonylamino,

C

1 s alkylaminocarbonyloxy or C 1 8 alkylsulfonylamino; and the pharmaceutically acceptable salts thereof, provided that R 7 is not camphosulfonylamino.

In a subclass of the invention is the compound of the formnula R8 0 0 N HR wherein X is selected from the group consisting of [I;\DAYLIB\Iibaa]8429.doc:kww 16

R

1 R R 1 R2 R2 R2 N N N N N N H H H Y is selected from

CO-

6 alkylene, CO-6 alkylene-0-Co.6 alkylene or Co-6 alkylene-NR'O-Co-6 alkylene; Z is selected from

(CH

2 )m or (CH 2 )m-O-(CH 2 )n;

R

1 4

R

15

R

16 and R 17 are each independently selected from hydrogen, halogen, C 1 -6 alkyl, oxo, or hydroxy; and all other variables are as defined above; and the pharmaceutically acceptable salts thereof; provided that R 7 is not camphosulfonylamino.

Illustrative of the invention is the compound of the formula:

OO

0 Y N R 1 3 H N-S0 2

-(CH

2 )q-R18

H

H

wherein q is an integer from 0 to 2;

R

8 is selected from *or and all other variables are as defined previously; and the pharmaceutically acceptable salts thereof; provided that when q is 1, R 1 8 is not [:\DAYLIB\ibaaI429.doCk-w Exemplifying the invention is the compound selected from r r r and the pharmaceutically acceptable salts thereof.

An illustration of the invention is the compound of the formula 0 and the pharmaceutically acceptable salts thereof.

Exemplifying the invention is a pharmaceutical composition comprising any of the compounds described above and a [I:\DAYLIBIibaa]8429.doc:kww WO 98/31359 PCT/US98/00617 pharmaceutically acceptable carrier. An example of the invention is a pharmaceutical composition made by combining any of the compounds described above and a pharmaceutically acceptable carrier. Another illustration of the invention is a process for making a pharmaceutical composition comprising combining any of the compounds described above and a pharmaceutically acceptable carrier.

Further illustrating the invention is a method of treating and/or preventing a condition mediated by antagonism of a vitronectin receptor in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds described above. Preferably, the condition is selected from bone resorption, osteoporosis, restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, cancer and tumor growth. More preferably, the condition is selected from osteoporosis and cancer. Most preferably, the condition is osteoporosis.

More specifically exemplifying the invention is a method of eliciting a vitronectin antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above. Preferably, the vitronectin antagonizing effect is an avp3 antagonizing effect; more specifically the avI3 antagonizing effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of atherosclerosis, inhibition of angiogenesis, inhibition of diabetic retinopathy, inhibition of macular degeneration, inhibition of inflammation, inhibition of viral disease, or inhibition of tumor growth. Most preferably, the avP3 antagonizing effect is inhibition of bone resorption. Alternatively, the vitronectin antagonizing effect is an av35 antagonizing effect or a dual avp3/av35 antagonizing effect. Examples of avp5 antagonizing effects are inhibition of: restenosis, atherosclerosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation, or tumor growth.

Examples of dual avp3/av5 antagonizing effects are inhibition of: bone resorption, restenosis, atherosclerosis, angiogenesis, diabetic -18- WO 98/31359 PCT/US98/00617 retinopathy, macular degeneration, inflammation, viral disease, or tumor growth.

Additional examples of the invention are methods of inhibiting bone resorption and of treating and/or preventing osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions decribed above.

Additional illustrations of the invention are methods of inhibiting tumor growth and of treating and/or preventing cancer in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions decribed above.

More specifically exemplifying the invention is any of the compositions described above, further comprising a therapeutically effective amount of a second bone resorption inhibitor; preferably, the second bone resorption inhibitor is alendronate.

More specifically illustrating the invention is any of the methods of treating and/or preventing osteoporosis and/or of inhibiting bone resoption described above, wherein the compound is administered in combination with a second bone resorption inhibitor; preferably, the second bone resorption inhibitor is alendronate.

Additional illustrations of the invention are methods of treating hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilizationinduced osteopenia, and glucocorticoid treatment in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.

More particularly exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of osteoporosis in a mammal in need thereof. Still further exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of: bone resorption, -19- WO 98/31359 PCT/US98/00617 tumor growth, cancer, restenosis, artherosclerosis, inflammation, viral disease, diabetic retinopathy, macular degeneration and/or angiogenesis.

Another illustration of the invention is a drug which is useful for treating and/or preventing osteoporosis in a mammal in need thereof, the effective ingredient of the said drug being any of the compounds descibed above. More specifically illustrating the invention is a drug which is useful for treating and/or preventing: bone resorption, tumor growth, cancer, restenosis, artherosclerosis, inflammation, viral disease, diabetic retinopathy, macular degeneration and/or angiogenesis in a mammal in need thereof, the effective ingredient of the said drug being any of the compounds described above.

Additional illustrations of the invention are methods of treating tumor growth in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound described above and one or more agents known to be cytotoxic or antiproliferative, taxol and doxorubicin. Further illustrative are methods of treating tumor growth wherein the compounds of the present invention are administered in conjunction with radiation therapy.

Further illustrative are methods of inhibiting angiogenesis comprising administering a compound as described above in combination with a VEGF (a vascular endothethial growth factor) inhibitor compound. Such combinations are useful for treating disease states such as macular degeneration, diabetic retinopathy, and cancer.

DETAILED DESCRIPTION OF THE INVENTION Representative compounds of the present invention are avp3 antagonists which display submicromolar affinity for the human av33 receptor. Compounds of this invention are therefore useful for treating mammals suffering from a condition caused or mediated by the av33 receptor, who are in need of such therapy. Pharmacologically effective amounts of the compounds, including pharamaceutically acceptable salts thereof, are administered to the mammal, to inhibit: the WO 98/31359 PCT/US98/00617 activity of mammalian osteoclasts, restenosis, tumor growth, artherosclerosis, inflammation, macular degeneration, diabetic retinopathy and angiogenesis.

The compounds of the present invention are administered in dosages effective to antagonize the av33 receptor where such treatment is needed, as, for example, in the prevention or treatment of osteoporosis or cancer. For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts." Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.

Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the following: Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate, Bitartrate, Borate, Bromide, Calcium, Camsylate, Carbonate, Chloride, Clavulanate, Citrate, Dihydrochloride, Edetate, Edisylate, Estolate, Esylate, Fumarate, Gluceptate, Gluconate, Glutamate, Glycollylarsanilate, Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide, Isothionate, Lactate, Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Mucate, Napsylate, Nitrate, N-methylglucamine ammonium salt, Oleate, Oxalate, Pamoate (Embonate), Palmitate, Pantothenate, Phosphate/diphosphate, Polygalacturonate, Salicylate, Stearate, Sulfate, Subacetate, Succinate, Tannate, Tartrate, Teoclate, Tosylate, Triethiodide and Valerate.

Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, sodium or potassium salts; alkaline earth metal salts, calcium or magnesium salts; and salts formed with suitable organic ligands, quaternary ammonium salts.

The compounds of the present invention, may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. Therefore, where a compound is chiral, the -21- WO 98/31359 PCT/US98/00617 separate enantiomers, substantially free of the other, are included within the scope of the invention; further included are all mixtures of the two enantiomers. Also included within the scope of the invention are polymorphs and hydrates of the compounds of the instant invention.

The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985.

Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.

The term "therapeutically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.

The term "bone resorption," as used herein, refers to the process by which osteoclasts degrade bone.

The term "alkyl" shall mean straight, branched or monocyclic alkanes, alkenes or alkynes of the specified number of carbon atoms. Preferably, the term "alkyl" refers to straight or branced chain alkanes of C1-10 carbon atoms, or any number within this range methyl, ethyl, 1-propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).

The term "alkenyl" shall mean straight or branched chain alkenes of two to ten total carbon atoms, or any number within this range.

The term "alkynyl" shall mean straight or branched chain alkynes of two to ten total carbon atoms, or any number within this range.

-22- WO 98/31359 PCT/US98/00617 The term "cycloalkyl" shall mean cyclic rings of alkanes of three to eight total carbon atoms, or any number within this range cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl).

The terms "polycyclic" or "polycyclyl," as used herein, refer to unsubstituted or substituted fused or bridged polycyclic systems containing from 7 to 20 carbon atoms and which can contain one or more degrees of unsaturation. Preferably, the term "polycyclyl" refers to unsubstituted or substituted fused or bridged bi- or tri-cyclic systems containing from 7-15 carbon atoms and which can contain one or two degrees of unsaturation. More preferably, the term "polycyclyl" refers to unsubstituted or substituted fused or bridged bi- or tri-cyclic systems containing from 7-10 carbon atoms and which can contain one or two degrees of unsaturation. Examples of prefered polycyclyl systems include, but are not limited to, decaline, camphor, adamantyl and norbornyl.

The term "cycloheteroalkyl," as used herein, shall mean a 3- to 8-membered fully saturated heterocyclic ring containing one or two heteroatoms chosen from N, O, or S. Examples of cycloheteroalkyl groups include, but are not limited to piperidinyl, pyrrolidinyl, azetidinyl, morpholinyl, piperazinyl.

The term "alkoxy," as used herein, refers to straight or branched chain alkoxides of the number of carbon atoms specified alkoxy), or any number within this range methoxy, ethoxy, etc.).

The term "alkylene" shall include both straight and branched chain alkylenes -CH2-, -CH(CH3)-, -CH(CH3)-CH2-, etc.).

The term "aryl," as used herein, refers to a monocyclic or polycyclic system composed of 5- and 6-membered rings, such that the system comprises at least one fully unsaturated aromatic) ring, wherein the rings contain 0, 1, 2, 3 or 4 heteroatoms chosen from N, O or S, and either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, C1-10 alkyl, C3-8 cycloalkyl, aryl, aryl C1-8 alkyl, amino, amino C1-8 alkyl, C1-3 acylamino, C1-3 acylamino C1-8 alkyl, C1-6 alkylamino, C1-6 alkylamino C1-8 alkyl, C1-6 dialkylamino, C1-6 dialkylamino-Cl-8 alkyl, C1-4 alkoxy, -23- WO 98/31359 PCT/US98/00617 C1-4 alkoxy C1-6 alkyl, hydroxycarbonyl, hydroxycarbonyl C1-6 alkyl, C1alkoxycarbonyl, C1-3 alkoxycarbonyl C1-6 alkyl, hydroxycarbonyl C1-6 alkyloxy, hydroxy, hydroxy C1-6 alkyl, cyano, trifluoromethyl, oxo or C1alkylcarbonyloxy. Examples of aryl include, but are not limited to, phenyl, naphthyl, pyridyl, pyrazinyl, pyrimidinyl, imidazolyl, benzimidazolyl, indolyl, thienyl, furyl, dihydrobenzofuryl, benzo(1,3) dioxolane, oxazolyl, isoxazolyl and thiazolyl, which are either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, CI-10 alkyl, C3-8 cycloalkyl, aryl, aryl C1-8 alkyl, amino, amino C1-8 alkyl, C1-3 acylamino, C1-3 acylamino C1-8 alkyl, C1-6 alkylamino, C1-6 alkylamino-Cl-8 alkyl, C1-6 dialkylamino, C1-6 dialkylamino C1-8 alkyl, C1-4 alkoxy, C1-4 alkoxy C1- 6 alkyl, hydroxycarbonyl, hydroxycarbonyl C1-6 alkyl, alkoxycarbonyl, C1-3 alkoxycarbonyl C1-6 alkyl, hydroxycarbonyl C1-6 alkyloxy, hydroxy, hydroxy C1-6 alkyl, cyano, trifluoromethyl, oxo or C1alkylcarbonyloxy. Preferably, the aryl group is unsubstituted, mono-, di-, tri- or tetra-substituted with one to four of the above-named substituents; more preferably, the aryl group is unsubstituted, mono-, di- or tri-substituted with one to three of the above-named substituents; most preferably, the aryl group is unsubstituted, mono- or di-substituted with one to two of the above-named substituents.

Whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent aryl CO-8 alkyl) it shall be interpreted as including those limitations given above for "alkyl" and "aryl." Designated numbers of carbon atoms C1-10) shall refer independently to the number of carbon atoms in an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.

The terms "arylalkyl" and "alkylaryl" include an alkyl portion where alkyl is as defined above and to include an aryl portion where aryl is as defined above. The CO-m or C1-m designation where m may be an integer from 1-10 or 2-10 respectively refers to the alkyl component of the arylalkyl or alkylaryl unit. Examples of arylalkyl include, but are not limited to, benzyl, fluorobenzyl, chlorobenzyl, -24- WO 98/31359 PCT/US98/00617 phenylethyl, phenylpropyl, fluorophenylethyl, chlorophenylethyl, thienylmethyl, thienylethyl, and thienylpropyl. Examples of alkylaryl include, but are not limited to, toluene, ethylbenzene, propylbenzene, methylpyridine, ethylpyridine, propylpyridine and butylpyridine.

When substituent R 1

R

2

R

3

R

4

R

5

R

6

R

7

R

8

R

9

R

1 0

R

1 1

R

1 2

R

1 3 or R 1 4 includes the definition CO aryl CO-8 alkyl), the group modified by CO is not present in the substituent. Similarly, when any of the variables m, q, r or s is zero, then the group modified by the variable is not present; for example, when s is zero, the group "-(CH2)s C=CH" is The term "halogen" shall include iodine, bromine, chlorine and fluorine.

The term "oxy" means an oxygen atom. The term "thio" means a sulfur atom. The term "oxo" shall mean a bivalent oxygen atom The term or D-amino acids" means naturally occurring L- or D-amino acids, for example, those naturally occurring L-amino acids present in humans, e.g. protein amino acids,, including Lalanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, Lglutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, Lleucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine, and those naturally occurring D-amino acids which are non-protein amino acids, such as those found, for example, in antibiotic substances produced by bacteria and fungi, including D-valine, D-asparagine, D-glutamate, D-ornithine, D-phenylalanine, D-leucine, D-cysteine, and D-aspartate. (see Zubay "BIOCHEMISTRY" Addison-Wesley Publishing Company, Inc.

(Reading, MA) 1983 pp. 867-870 and Stryer "BIOCHEMISTRY" W.H.

Freeman and Company (New York, NY) 3rd Edition 1988 pp. 16-21).

The term "substituted" shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally.

WO 98/31359 PCT/US98/00617 Under standard nonmenclature used throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. For example, a C1-5 alkylcarbonylamino C1-6 alkyl substituent is equivalent to

O

II

-C1-6 alkyl-NH-C-C.s 5 alkyl.

The present invention is also directed to combinations of the compounds of the present invention with one or more agents useful in the prevention or treatment of osteoporosis. For example, the compounds of the instant invention may be effectively administered in combination with effective amounts of other agents used in the treatment of osteoporosis such as bisphosphonate bone resorption inhibitors; preferably, the bone resorption inhibitor is the bisphosphonate alendronate, now sold as FOSAMAX®. Preferred combinations are simultaneous or alternating treatments of an av3 receptor antagonist of the present invention and FOSAMAX®. In accordance with the method of the present invention, the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other agents useful for treating av33 related conditions includes in principle any combination with any pharmaceutical composition useful for treating osteoporosis.

Further exemplifying the invention are compositions further comprising an active ingredient selected from the group consisting of an organic bisphosphonate or a pharmaceuticallyacceptable salt or ester thereof, an estrogen receptor modulator, and -26- WO 98/31359 PCT/US98/00617 a cytotoxic/antiproliferative agent, and mixtures thereof.

Nonlimiting examples of such bisphosphonates include alendronate, etidronate, pamidronate, risedronate, and pharmaceutically acceptable salts and esters thereof. A particularly preferred bisphosphonate is alendronate, especially alendronate monosodium trihydrate.

Nonlimiting examples of estrogen receptor modulators include estrogen, progesterin, estradiol, raloxifene, and tamoxifene.

Nonlimiting examples of cytotoxic/antiproliferative agents are taxol and doxorubicin.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, topical ocular eyedrop), subcutaneous, intramuscular or transdermal patch) form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an avP33 inhibitor.

The dosage regimen utilizing.the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

-27- WO 98/31359 PCTIUS98/00617 Oral dosages of the present invention, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably 0.01 to mg/kg/day, and most preferably 0.1 to 5.0 mg/kg/day. For oral administration, the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably, from about 1 mg to about 100 mg of active ingredient. Intravenously, the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.

Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.

Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittant throughout the dosage regimen.

In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as 'carrier' materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be -28- WO 98/31359 PCT/US98/00617 combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.

In the schemes and examples below, various reagent symbols and abbreviations have the following meanings: AcOH (HOAc): Acetic acid.

-29- WO 98/31359 WO 98/ 1359PCTIUS98/00617 BH3 *DMS: BOC(Boc):

BOP:

CBZ(Cbz):

CDI:

CH

2 Cl 2 CHC1 3

DEAD:

DIAD:

DIBAJI or

DJBAL-H:

DJPEA:

DMAP:

DME:

DMF:

DMSO:

DPFN:

EDC:

Et: EtOAc: EtOH:

HOBT:

LDA:

MeOH: NEt3:

NMM:

PCAoHC1: Pd/C: Pd(OAc)2: Ph: pTSA:

TEA:

TFA:

Borane dimethylsulfide.

t-Butyloxycarbonyl.

Benzotriazol- 1-yloxytris(dimethylamino)phosphonium hexafluorophosphate.

Carbobenzyloxy or benzyloxycarbonyl.

Carbonyidfimidazole.

Methylene chloride.

Chloroform.

Diethyl azodicarboxylate.

Diisopropyl azodicarboxylate.

Diisobutylaluminum hydride.

Dii sopropylethylamine.

4-Dimethylaminopyri dine.

1 ,2-Dimethoxyethane.

Dimethyilformamide.

Dimethylsulfoxide.

3 ,5-Dimethyl- 1-pyrazolylformamidine nitrate.

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide.

Ethyl.

Ethyl acetate.

Ethanol.

1-Hydroxybenzotriazole.

Lithium diisopropylamide.

Methanol.

Triethylamine.

N-methylmorpholine.

Pyrazole carboxamidine hydrochloride.

Palladium on activated carbon catalyst.

Palladium(II) acetate.

Phenyl.

p-Toluene sulfonic acid.

Triethyl amine.

Trifluoroacetic acid.

WO 98/31359 PCT/US98/00617 THF: Tetrahydrofuran.

TLC: Thin Layer Chromatography.

TMEDA: N,N,N',N'-Tetramethylethylenediamine.

TMS: Trimethylsilyl.

TsC1: Tosyl chloride.

The novel compounds of the present invention were prepared according to the procedure of the following schemes and examples, using appropriate materials and are further exemplified by the following specific examples. The most preferred compounds of the invention are any or all of those specifically set forth in these examples.

These compounds are not, however, to be construed as forming the only genus that is considered as the invention, and any combination of the compounds or their moieties may itself form a genus. The following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted.

The following Schemes and Examples describe procedures for making representative compounds of the present invention.

Moreover, by utilizing the procedures described in detail in PCT International Application Publication Nos. W095/32710, published 7 December 1995, and W095/17397, published 29 June 1995, in conjunction with the disclosure contained herein, one of ordinary skill in the art can readily prepare additional compounds of the present invention claimed herein.

More specifically, procedures for preparing the N-terminus of the compounds of the present invention are described in WO 95/32710.

Additionally, for a general review describing the synthesis of p-alanines which can be utilized as the C-terminus of the compounds of the present invention, see Cole, Recent Stereoselective Synthetic Approaches to f-Amino Acids, Tetrahedron, 1994, 50, 9517-9582; Juaristi, E, et al., Enantioselective Synthesis of p-Amino Acids, Aldrichemica Acta, 1994, 27, 3. In particular, synthesis of the 3-methyl P-alanine is taught in -31- WO 98/31359 WO 9831359PCT/US98i006l7 Duggan, M.F et al., J. Med. Chem., 1995, 38, 3332-3341; the 3-ethynyl f3alanine is taught in Zablocki, et al., J. Med. Chem., 1995, 38, 2378- 2394; the 3-pyrid-3-yl 1-alanine is taught in Rico, J.G. et al., J. Org.

Chem., 1993, 58, 7948-795 1; and the 2-amino and 2-toslylamino j3are taught in Xue, C-B, et al., Biorg. Med. Chem. Letts., 1996, 6, 339-344.

Scheme 1

H

2 N IVC2H

NHCBZ

1-1 SoC1 2 HIHNi C02Et EtOH HIHNy

NHCBZ

1-2

BOC

2 O, NEt 3

CH

3

CN

BOCN C2Et 10% Pd/C N H 2 EtOAc NH

H

2 1-4 1 camphorsulfonyl NMM, CH 2

CI

2 02t C (g) '44 EtOAc H NHCBZ 1-3 chloride HCl.H 2 Ni 4 >(02Et BOCN

~C

-32 WO 98/31359 WO 9831359PCTIUS98/00617 Scheme 1 (continued)

OH

Pd (OAc) 2

CH

3 CN, 10000 kL -OEt 1-9 L-proli ne, EtOH, ref lux zNH N1-N -33 WO 98/31359 WO 9831359PCTIUS98/00617 Scheme 1 (continued) 1-11 I Pd/C, ethanol,

H

2 1-12Z, R =Et )6N HCI, 50 0

C

BOP

DMF 1-6

NMM

NaOH, C 2 1- 5 01- Ethyl 20S-Ncx-Cbz-2 .3-diaminopropionate hydrochloride (1-2) 1-1 (5 g, 21 mmol; Bachem) was dissolved in 100 mL EtOH and cooled to 0 0 C. SOC12 (9.2 mL, 126 mmnol) was added followed by removal of the cooling bath. After 6 hours, the reaction was concentrated to provide 1-2 as a white solid.

1 H NMR (300 MHz, CD3OD) 5 7.35 (in, 5H), 5.14 2H), 4.44 (in, 1H), 4.22 J=7Hz, 2H), 3.43 (mn, 1H), 3.20 (in, 1H), 1.25 J=7Hz, 3H).

-34- WO 98/31359 PCT/US98/00617 Ethyl 2(S)-Nn-Cbz-Np-Boc-2.3-diaminopropionate (1-3) 1-2 (2 g, 6.6 mmol) was dissolved in 60 mL CH3CN. NEt3 (1 mL, 7.2 mmol) was added followed by BOC20 (1.58 g, 7.3 mmol). After two hours, the reaction was concentrated, diluted with EtOAc, washed with sat. NaHC03, 10% KHS04 and brine, dried (MgS04), filtered and concentrated to provide 1-3 as a clear oil.

TLC Rf 0.87 (silica, 80% EtOAc/hexanes).

1 H NMR (300 MHz, CDC13) 5 7.35 5H), 5.75 (bs, 1H), 5.12 2H), 4.81 (bs, 1H), 4.39 1H), 4.19 2H), 3.56 2H), 1.42 9H), 1.29 (q, J=7Hz, 3H).

Ethyl 2(S)-Np-Boc-2.3-diaminopropionate (1-4) 1-3 (2.4 g, 6.6 mmol) with 10% Pd/C (240 mg) in EtOAc mL) was stirred under a H2 atmosphere for 20 hours. The reaction was filtered through a celite pad and concentrated to provide 1-4 as a clear oil.

TLC Rf 0.13 (silica, 80% EtOAc/hexanes).

1 H NMR (300 MHz, CDC13) 5 5.00 (bs, 1H), 4.19 2H), 3.55 2H), 3.25 1H), 1.44 9H), 1.29 J=7Hz, 3H).

Ethyl-2(S)-Na-(1(S)10-camphorsulfonylamino)-Np-Boc-2,3-diaminopropionate Amine 1-4 (760 mg, 3.27 mmol) was dissolved in 35 mL CH2C12 and cooled to o0C. NMM (755 mL, 6.87 mmol) and camphorsulfonyl chloride (1.23 g, 4.9 mmol; Aldrich) were added. After stirring at 0°C for one hour, the reaction was concentrated, then diluted with EtOAc, washed with H20, sat. NaHC03, 10% KHSO4 and brine, dried (MgS04), and concentrated to an oil. Flash chromatography (silica, 25-40% EtOAc/hexanes) provided 1-5 as a clear oil.

TLC Rf 0.66 (silica, 50% EtOAc/hexanes).

1 H-NMR (300 MHz, CDC13) 5 6.37 J=8Hz, 1H), 4.99 (bt, 1H), 4.32 (m, 1H), 4.23 J=8Hz, 2H), 3.56 3H), 3.0 J=15 Hz, 1H), 2.4 1H), 2.05 4H), 1.43 9H), 1.30 J=7 Hz, 3H), 1.00 3H), 0.91 3H).

WO 98/31359 PCT/US98/00617 Ethyl-2(S)-Na-(l(S)10-camphorsulfonylamino)-2,3-diaminopropionate hydrochloride (1-6) Ester 1-5 (900 mg, 2.18 mmol) was dissolved in 15 mL EtOAc and cooled to o0C. HC1 was bubbled through the reaction mixture for 15 minutes. The reaction was removed from the cooling bath and purged with Ar for 20 minutes followed by concentration to provide 1- 6 as a foamly solid.

TLC Rf 0.05 (silica, 20% MeOH/EtOAc).

1 H-NMR (300 MHz, CDC13): 6 4.75 1H), 4.26 J=7Hz, 2H), 3.50 (m, 4H), 2.40 3H), 1.98 4H), 1.30 J=7Hz, 3H), 1.04 3H), 0.91 (s, 3H).

Ethyl 4-(3-oxo-butvl)benzoate (1-9) 3-Buten-2-ol 1-7 (2.15 mL, 25 mmol; Aldrich), ethyl 4iodobenzoate 1-8 (5.5 g, 20 mmol, Aldrich) and NEt 3 (3.5 mL, 25 mmol) were combined in CH 3 CN (6 mL) under argon in a pressure tube.

Pd(OAc) 2 (19 mg, 80 umol) was added and the reaction heated at 100 0

C

for 3 hours. The reaction was cooled, then diluted with ether and washed with H 2 0, 10% KHSO 4 sat. NaHC0 3 and brine, dried (MgSO 4 and concentrated to furnish 1-9 as a brown solid.

TLC Rf 0.23 (silica, 30% EtOAc/hexanes).

Ethyl 4-r2-(1.8-Naphthvridin-7-vl)ethvllbenzoate (1-11) An ethanol solution (70 mL) of 1-10 (1.75 g, 14.3 mmol; JOC, 1983,48, 3401-3408), 1-9 (3.15 g, 14.3 mmol, and L-proline (0.8 g, mmol) was refluxed for 16 hours. The reaction was concentrated to dryness. Flash chromatography (silica, 60%-80% EtOAc/hexane) gave 1- 11 as a yellow solid.

Rf 0.21 (silica, 3/1 EtOAc/hexane).

1 H NMR (300 MHz, CDC13) 6 9.1 1H), 8.18 J=8 Hz, 1H), 8.08 J=8 Hz, 1H), 7.95 J=8 Hz, 2H), 7.48 1H), 7.30 (dd, J=8 Hz, 2H), 4.35 (q, J=7Hz, 2H), 3.35 4H), 1.38 J=7Hz, 3H).

-36- WO 98/31359 WO 9831359PCT/US98/00617 Ethyl 1,2,3 ,4-tetrahydro- 1,8-naphthyridin-7-yl)ethylbenzoate (1-12) A mixture of 1411 (645 mg, 2.1 inmol), 10% Pd/C (65 mg), and ethanol mL) was stirred under a hydrogen atmosphere for 18 hour. Filtration through a celite pad followed by concentration provided crude 1-12.

Trituration of the solid with 1:1 ether/hexanes furnished 1-12 as a light yellow solid.

TLC Rf 0.75 (silica, 70% EtOAc/hexanes).

1H NMR (300 MHz, CDC13) 8 7.94 J=8Hz, 2H), 7.26 J=8 Hz, 2H), 7.03 (d J=7 Hz, 1H), 6.28 (d J=7 Hz, 1H), 4.81 1H), 4.35 J=7 Hz, 2H), 3.40 (in, 2H), 3.03 (mn, 2H), 2.84 (in, 2H), 2.69 J=6 Hz, 2H), 1.93 J=6 Hz, 2H), 1.38 J=7 Hz, 3H).

.4-Tetrahvdro-1 .8-nanhthyridin-7-vl)ethvlbenzoic acid (1-13) The ester 1-12 (680 mg, 2.1 mmol) in 6N HC1 (10 mL) was heated to 50 0 for 18 hours. Concentration provided 1-13 as a light yellow solid.

1 H NMR (300 MHz, CD3OD) 8 7.93 J=8 Hz, 2H), 7.52 J=8 Hz, 1H), 7.31 J=8 Hz, 2H), 5.54 J=8 Hz, 3.48 J-5 Hz, 2H), 3.03 4H), 2.79 J=6 Hz, 2H), 1.93 J=6 Hz, 2H).

1,2,3 ,4-Tetrahydro-1 ,8-naphthyridin-7-yl)ethyllbenzoyl-2(S)[ 1(S)10camphorsulfonvlaminol f3-alanine ethyl ester (1-14) 1-13 (200 mng, 0.627 mmol), amine 1-6 (240 ing, 0.69 minol), NMM (345 mL, 3.13 minol) and BOP reagent (332 ing, 0.75 mmnol) were combined in 5 mL CH3CN. After stirring -overnight, the reaction was concentrated, then diluted with EtOAc, washed with H20, sat. NaHCO3 and brine, dried (MgSO4), filtered and concentrated. Flash chromatography (silica, EtOAc) provided 1-14 as an off-white foamy solid.

TLC Rf 0.13 (silica, EtOAc).

1 H NMR (300 MHz, CDCl3) 5 7.70 J=8Hz, 2H), 7.25 J=8Hz, 2H), 7.03 J=7Hz, 1H), 6.72 J=5Hz, 1H), 6.5 (bin, 1H), 6.28 J=7Hz, 1H), 4.79 1H), 4.42 (bs, 1H), 4.25 J=7Hz, 2H), 4.04 (in, 1H), 3.85 (in, 1H), 3.55 -37 WO 98/31359 PCT/US98/00617 J=15Hz, 1H), 3.41 2H), 3.00 3H), 2.82 J=4Hz, 2H), 2.69 (t, J=6Hz, 2H), 2.04 8H), 1.58 (bs, 3H), 1.31 J=7Hz, 3H), 1.00 3H), 0.90 3H).

4-[2-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)ethyl]benzoyl- 2(S)-rl(S)10-camphorsulfonvlaminol P-alanine (1-15) 1-14 (250 mg, 0.409 mmol) was dissolved in 4 mL EtOH, 1M NaOH (1.02 mL, 1.02 mmol) was added and the reaction mixture was stirred for two hours. The reaction mixture was neutralized with 1N HC1 and then concentrated to a foamy solid. Flash chromatography (silica, 18:10:1:1 EtOAc/EtOH/NH40H/H20) provided 1-15 as a slightly yellow solid.

TLC Rf 0.49 (silica, 12:10:1:1 EtOAc/EtOH/NH40H/H20).

1 H NMR (400 MHz, DMSO) 8.48 (bt, 1H), 7.72 J=8Hz, 2H), 7.55 (bs, 1H), 7.28 J=8Hz, 2H), 7.02 J=7Hz, 1H), 6.37 1H), 6.26 J=7Hz, 1H), 4.13 1H), 3.54 3H), 3.37 2H), 2.94 3H), 2.73 J=7Hz, 2H), 2.6 J=6Hz, 2H), 2.3 3H), 2.02 1H), 1.89 2H), 1.75 (m, 2H), 1.49 1H), 1.37 1H), 1.05 1H), 0.95 3H), 0.66 3H).

Structurally related analogs of 1-15 can be prepared from commercially available starting materials utilizing the chemistry shown in Scheme 1. Several such representative compounds are examplified as compounds 1-4 depicted in Table 1. Compounds 1 and 2 are readily available through the chemistry illustrated in Scheme 1 by using 2(R)-Na-Cbz-2,3-diaminopropionic acid 5 (Bachem) or camphorsulfonyl chloride 6 (Aldrich), respectively. Compounds 3 and 4 are attained by starting with the appropriate alcohols, 1adamantanemethanol 7 (Aldrich) or (1R)-(-)-Nopol 8 (Aldrich), respectively. These alcohols can be converted to their corresponding sulfonyl chlorides via the standard chemistry shown in Scheme 2.

-38- WO 98/31359 WO 9831359PCTIUS98/00617 Scheme 2

HO

2-1 TsCI, pyridine TsO 2-2 NaHCO 3

OH

3

COSH,

DMF

HS

CH

3 OH, K 2 C0 3

CH

3 00S 2-4 2-3 C12,

H

2 0 C'S02

;A-

-39- WO 98/31359 WO 98/ 1359PCTIUS98/00617 Table 1 Compound Starting Material H02 0

H

2 N-)<xC02H H NHCBZ 0 H

N

N

N

2 C0 2

H

H

H

7 0 H N >(C2H NH H H U NNzH 02 4

HO

8 WO 98/31359 WO 9831359PCTIUS98/00617 SCHEME 3 0 H NH 2 I /SO 2

CI

NaOH, dioxane

H

2 0

H

2 N <C 2

H

0 H S 0 2 1. Br 2 NaOH,

H

2 0 2. HCI

H

2 N oH H 02

HCI

EtOH

HCI.H

2

NX>(C

0 2CH2CH3 H 2 3-4 -41- WO 98/31359 WO 9831359PCTIUS98/00617 SCHEME 3 (Cont'd)

/CO

2

CH

2

CH

3

\N

H

2 N IAa

H

2 Pd/C EtOH

-CO

2

CH

2

CH

3 6N HCI

-CO

2

H

HCI.H

2

NXCOHCH

H HNSO 2

C

6

H

4

I

3-4 EDO, HORT, NMM, DMF

H

2

N-

-CO

2

CH

2

CH

3 3-7 -42- WO 98/31359 WO 98/ 1359PCTIUS98/00617 SCHEME 3 (Cont'd) f- 9I H

NH

I6N HOI 6000C

H

2

N

(CH

3 Sn) 2 Pd(PPH 3 4 dioxane, 90' C Snf(C H 3 3 H H' ly N C0 2

H

3-9 C0 2

H

3-10 -43 WO 98/31359 PCT/US98/00617 N-(4-Iodo-phenvlsulfonvlamino)-L-asparagine (3-2) To a stirred solution of acid 3-1 (4.39 g, 33.2 mmol), NaOH (1.49 g, 37.2 mmol), dioxane (30 ml) and H20 (30 ml) at 0°C was added pipsyl chloride (10.34 g, 34.2 mmol). After -5 minutes, NaOH (1.49, 37.2 mmol) dissolved in 15 ml H20, was added followed by the removal of the cooling bath. After 2.0 h, the reaction mixture was concentrated. The residue was dissolved in H20 (300 ml) and then washed with EtOAc.

The aqueous portion was cooled to 0 C and then acidified with concentrated HC1. The solid was collected and then washed with Et20 to provide acid 3-2 as a white solid.

1 H NMR (300 MHz, D20) 5 7.86 2H, J=8Hz), 7.48 2H, J=8Hz) 3.70 1H), 2.39 2H).

2(S)-(4-Iodo-phenvlsulfonvlamino)-p-alanine (3-3) To a stirred solution of NaOH (7.14 g, 181.8 mmol) and ml) at 0°C was added Br2 (1.30 ml, 24.9 mmol) dropwise over a ten minute period. After -5 minutes, acid 3-2 (9.9 g, 24.9 mmol), NaOH (2.00 g, 49.8 mmol) and H20 (35 ml) were combined, cooled to 0°C and then added in a single portion to the reaction. After stirring for 20 minutes at 0 C, the reaction was heated to 90C for 30 minutes and then recooled to 0°C. The pH was adjusted to -7 by dropwise addition of concentrated HC1. The solid was collected, washed with EtOAc, and then dried in vacuo to provide acid 3-3 as a white solid.

1 H NMR (300 MHz, D20) 6 8.02 2H, J=8Hz), 7.63 2H, J=8Hz), 4.36 1H), 3.51 (dd, 1H, J=5Hz, 13Hz) 3.21 1H).

Ethyl 2 4 -iodo-phenvlsulfonvlamino)-p-alanine-hydrochloride (3-4) HCI gas was rapidly bubbled through a suspension of acid 3-3 (4.0 g, 10.81 mmol) in EtOH (50 ml) at 0°C for 10 minutes. The cooling bath was removed and the reaction was heated to 60'C. After 18 h, the reaction was concentrated to provide ester 3-4 as a white solid.

1 H NMR (300 MHz, CD30D) 8 7.98 2H, J=8Hz), 7.63 2H, J=8Hz), 4.25 1H, J=5Hz), 3.92 2H), 3.33 1H), 3.06 1H), 1.01 3H, J=7Hz).

-44- WO 98/31359 WO 9831359PCTIUS98/00617 Ethyl 2-Aminouvridin-6-vl )ethvllbenzoate A mixture of ester 3-5a (700 mg, 2.63 mmol), (for preparation, see: Scheme 29 of PCT International Application Publication No. WO 95/327 10, published December 7, 1995) 10% Pd/C (350 mg) and EtOR were stirred under 1 atm. H2. After 20 h, the reaction was filtered through a celite pad and then concentrated to provide ester 3-5 as a brown oil.

TLC Rf 0.23 (silica, 40% EtOAc/hexanes) 1 H NMR (300 MHz, CDCl3) 6 7.95 2H, J=8Hz), 7.26 (in, 3H), 6.43 (d, 1H, J=7Hz), 6.35 1H, J=8Hz), 4.37 (in, 4H), 3.05 (in, 2H), 2.91 (in, 2H), 1.39 3H, J=7Hz).

4- r2-( 2-AminoT)vridin-6-vl )ethvllbenzoic acid hydrochloride (3-6) .A suspension of ester 3- (625 mg, 2.31 mmol) in 6N HCl (12 ml) was heated to 60'C. After -20 h, the reaction was concentrated to give acid 3-6 as a tan solid.

1 H NMR (300 MHz, CD3OD)) 8 7.96 2H, J=8Hz), 7.80 (in, 1H), 7.33 (d, 2H, J=8Hz), 6.84 1H, J=9Hz), 6.69 1H, J=7Hz), 3.09 (mn, 4H).

Ethyl 4-12-(2-Aminopyridin-6-yl)ethyllbenzoyl-2(S )-(4-iodophenvlsulfonvlamino)-f3-alanine (3-7) A solution of acid 3-6 (400 mg, 1.43 numol), amine 3-4 (686 ing, 1.57 mmol), EDC (358 mng, 1.86 mmol), HOBT (252 ing, 1.86 mmol), NMM (632 g.d, 5.72 mmol) and DMF (10 ml) was stirred for -20 h.

The reaction was diluted with EtOAc and then washed with sat NaHCO3, brine, dried (MgSO4) and concentrated. Flash chromatography (silica, EtOAC to 5% isopropanol/EtOAc) provided amide 3-7 as a white solid.

TLC Rf 0.4 (silica, 10% isopropanol/EtOAc) 1 H NIVR (300 MHz, CD3OD) 5 7.79 2H, J=9Hz) 7.61 2H, J=8Hz), 7.52 2H, J=9Hz), 7.29 (mn, 1H), 7.27 2H, J=8Hz), 4.20 (mn, 1H), 3.95 2H, J=7Hz), 3.66 (dd, 1H, J=6Hz, 14Hz), 3.49 (dd, 1H, J=8Hz, 13Hz), 3.01 (mn, 2H), 2.86 (in, 2H), 1.08 3H, J=7Hz).

WO 98/31359 WO 9831359PCTIUS98/00617 4-[2-(2-Aminopyridin-6-yl)ethyllbenzoyl-2(S)-(4-iodophenylsulfonvlainino)-D-alanine (3-8) A solution of ester -3-7 (200 mg, 0.3213 minol) and 6N HCl ml) was heated to 60'C. After -20 h, the reaction mixture was concentrated. Flash chromatography (silica, 20:20:1:1 EtOAc/EtOH/ NH4OH/H20) provided acid 3-8 as a white solid.

TLC Rf 0.45 (silica, 20:20:1:1 EtOAcIEtOH/NH4OH/H20) 1H NMR (400 MHz, DMSO) 5 8.40 (in, 1H), 8.14 (Bs, 1H), 7.81 2H, J=8Hz), 7.62 2H, J=8Hz), 7.48 2H, J=8Hz), 7.27 (in, 3H), 6.34 1H, J=7Hz), 6.25 1H, J=8Hz), 5.85 (bs, 2H), 3.89 (bs, 1H), 3.35 (mn, 2H), 2.97 (in, 2H), 2.79 (in, 2H).

4 2 2 -Amninopyridin-6-yl)ethyl)benzoyl-2(S)-(4-trimethylstannylphenvlsulfonylamino-D-alanine (3-9) A solution of iodide 3-8 (70 mg, 0.1178 inmol), (CH3Sn)2 (49 tl, 0.2356 minol), Pd(PPh3)4 (5 mng) and dioxane (7 ml) was heated to After 2 h, the reaction was concentrated and then purified by prep HPLC (Delta-Pak C18 15 pM 100AO, 40 x 100 mmn; 95:5 E 5:95 H20/CH3CN) provided the trifluoroacetate salt. The salt was suspended in H20 (10 ml), treated with NH40H (5 drops) and then lyophilized to provide amide 3-9 as a white solid.

1 H NMR (400 MHz, DMSO) 8 8.40 (in, 1H), 8.18 1H, J=8Hz), 7.67 (in, 7.56 2H, J=8Hz), 7.29 (d 2H, J=8Hz), 6.95-7.52 (in, 2H), 6.45 (bs, 2H), 4.00 (in, 1H), 3.50 (in, 1H), 3.33 (in, 1H), 2.97 (in, 2H), 2.86 (in, 2H).

4 2 -(2-Aminopyridin-6-yl)ethyllbenzoyl-2(S)-4- 125 iodophenylsulfonlamino-3-alanine (3-10) An iodobead (Pierce) was added to a shipping vial of 5 mCi of Na 12 5 J (Amersham, IMS3O) and stirred for five minutes at room temperature. A solution of 0.1 mg of 3-9 in 0.05 mL of 10% H2SO4IVeOH was made and immediately added to the Na 1 2 5 1/iodobead vial. After stirring for three minutes at room temperature, approximately 0.04-0.05 mL of NHI40H was added so the reaction mixture was at pH 6-7. The entire reaction mixture was injected onto the HPLC for purification [Vydac peptide-protein C-18 column, 4.6 x 250 mm, linear gradient of -46 WO 98/31359 PCT/US98/00617 acetonitrile (TFA):H20 TFA) to 90% acetonitrile (0.1%

TFA):H

2 0 TFA) over 30 minutes, 1 mL/min]. The retention time of 3-10 is 17 minutes under these conditions. Fractions containing the majority of the radioactivity were pooled, lyophilized and diluted with ethanol to give approximately 1 mCi of 3-10, which coeluted on HPLC analysis with an authentic sample of 3-8.

Instrumentation: Analytical and preparative HPLC was carried out using a Waters 600E Powerline Multi Solvent Delivery System with 0.1 mL heads with a Rheodyne 7125 injector and a Waters 990 Photodiode Array Detector with a Gilson FC203 Microfraction collector. For analytical and preparative HPLC a Vydac peptide-protein C-18 column, 4.6 x 250 mm was used with a C-18 Brownlee modular guard column. The acetonitrile used for the HPLC analyses was Fisher Optima grade. The HPLC radiodetector used was a Beckman 170 Radioisotope detector. A Vydac C-18 protein and peptide column, 3.9 x 250 mm was used for analytical and preparative HPLC. Solutions of radioactivity were concentrated using a Speedvac vacuum centrifuge.

Calibration curves and chemical concentrations were determined using a Hewlett Packard Model 8452A UV/Vis Diode Array Spectrophotometer.

Sample radioactivities were determined in a Packard A5530 gamma counter.

The test procedures employed to measure av33 binding and the bone resorption inhibiting activity of the compounds of the present invention are described below. In addition, the activity of the compounds of the present invention for treating cancer and/or inhibiting tumor growth is confirmed utilizing the nude mouse tumor xenograft assay described in Kohl et al., PNAS 91 (1994) 9141-45.

-47- WO 98/31359 PCT/US98/00617 BONE RESORPTION-PIT ASSAY When osteoclasts engage in bone resorption, they will literally cause the formation of pits in the surface of bone that they are acting upon. Therefore, when testing compounds for their ability to inhibit osteoclasts, it is useful to measure the ability of osteoclasts to excavate these resorption pits when the inhibiting compound is present.

Consecutive 200 micron thick cross sections from a six mm cylinder of bovine femur diaphysis were cut with a low speed diamond saw (Isomet, Beuler, Ltd., Lake Bluff, Il). Bone slices were pooled, placed in a 10% ethanol solution and refrigerated until further use.

Prior to experimentation, bone slices were ultrasonicated twice, 20 minutes each in H20. Cleaned slices were placed in 96 well plates such that two control lanes and one lane for each drug dosage are available. Each lane represents either triplicate or quadruplicate cultures. The bone slices in 96 well plates were sterilized by UV irradiation. Prior to incubation with osteoclasts, the bone slices were hydrated by the addition of 0.1 ml Medium 199, pH 6.9 containing fetal bovine serum and 1% penicillin/streptomycin.

Osteoclasts were isolated from the long bones of 1 to 3 day old rat pups (Sprague-Dawley) by modifications of Chambers et al., Cell. Science, 66:383-399). The resulting suspension (0.75 ml/bone) was gently triturated 90-120 times using a wide bore transfer pipet. The cellular population was separated from bone fragments by a cell strainer with a 100 micron nylon mesh. 100 gl of the cell suspension was placed onto each bone slice. Test compounds were then added at the desired experimental concentrations.

Bone slices exposed to osteoclasts for 20-24 hrs were processed for staining. Tissue culture media was removed from each bone slice. Each well was washed with 200 .1 of H20, and the bone slices were then fixed for 20 minutes in 2.5% glutaraldehyde, 0.1 M cacodylate, pH 7.4. After fixation, any remaining cellular debris was removed by 2 min. ultrasonication in the presence of 0.25 M NH40H followed by 2 X min ultrasonication in H20. The bone slices were immediately stained for 6-8 min with filtered 1% toluidine blue and 1% borax.

-48- WO 98/31359 PCT/US98/00617 After the bone slices have dried, resorption pits were counted in test and control slices. Resorption pits were viewed in a Microphot Fx (Nikon) fluorescence microscope using a polarizing Nikon IGS filter cube. Test dosage results were compared with controls and resulting IC50 values were determined for each compound tested.

The appropriateness of extrapolating data from this assay to utility and use in mammalian (including human) disease states is supported by the teaching found in Sato, t al., Journal of Bone and Mineral Research, Vol. 5, No. 1, 1990. That article teaches that certain bisphosphonates have been used clinically and appear to be effective in the treatment of Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastases, and bone loss due to immobilization or sex hormone deficiency. These same bisphosphonates are then tested in the resorption pit assay described above to confirm a correlation between their known utility and positive performance in the assay.

EIB ASSAY Duong et al., J. Bone Miner. Res., 8:S 378, describe a system for expressing the human integrin avp3. It has been suggested that the integrin stimulates attachment of osteoclasts to bone matrix, since antibodies against the integrin, or RGD-containing molecules, such as echistatin (European Publication 382 451), can effectively block bone resorption.

Reaction Mixture: 1. 175 jl TBS buffer (50 mM Tris*HCl pH 7.2, 150 mM NaC1, 1% BSA, 1 mM CaC12, 1 mM MgC12).

2. 25 pl cell extract (dilute with 100 mM octylglucoside buffer to give 2000 cpm/25 al).

3. 1 2 5 I-echistatin (25 41/50,000 cpm) (see EP 382 451).

4. 25 il buffer (total binding) or unlabeled echistatin (nonspecific binding).

-49- WO 98/31359 PCT/US98/00617 The reaction mixture was then incubated for 1 h at room temp. The unbound and the bound av33 were separated by filtration using a Skatron Cell Harvester. The filters (prewet in 1.5% polyethyleneimine for 10 mins) were then washed with the wash buffer mM Tris HC1, 1mM CaC12/MgCl2, pH The filter was then counted in a gamma counter.

SPA ASSAY

MATERIALS:

1. Wheatgerm agglutinin Scintillation Proximity Beads (SPA): Amersham 2. Octylglucopyranoside: Calbiochem 3. HEPES: Calbiochem 4. NaCl: Fisher CaC12: Fisher 6. MgC12: SIGMA 7. Phenylmethylsulfonylfluoride (PMSF): SIGMA 8. Optiplate: PACKARD 9. 3-10 (specific activity 500-1000 Ci/mmole) test compound 11. Purified integrin receptor: avp3 was purified from 293 cells overexpressing avp3 (Duong et al., J. Bone Min. Res., 8:S378, 1993) according to Pytela (Methods in Enzymology, 144:475, 1987) 12. Binding buffer: 50 mM HEPES, pH 7.8, 100 mM NaC1, 1 mM Ca 2 +/Mg 2 0.5 mM PMSF 13. 50 mM octylglucoside in binding buffer: 50-OG buffer

PROCEDURE:

1. Pretreatment of SPA beads: 500 mg oflyophilized SPA beads were first washed four times with 200 ml of 50-OG buffer and once with 100 ml of binding buffer, and then resuspended in 12.5 ml of binding buffer.

WO 98/31359 PCT/US98/00617 2. Preparation of SPA beads and receptor mixture In each assay tube, 2.5 l1 (40 mg/ml) of pretreated beads were suspended in 97.5 p of binding buffer and 20 ml of buffer. 5 l1 (-30 ng/pl) of purified receptor was added to the beads in suspension with stirring at room temperature for minutes. The mixture was then centrifuged at 2,500 rpm in a Beckman GPR Benchtop centrifuge for 10 minutes at 4 0 C. The pellets were then resuspended in 50 p.l of binding buffer and p. of 50-OG buffer.

3. Reaction The following were sequentially added into Optiplate in corresponding wells: Receptor/beads mixture (75 l) (ii) 25 p.1 of each of the following: compound to be tested, binding buffer for total binding or 3-8 for non-specific binding (final concentration 1 pM) (iii) 3-10 in binding buffer (25 p.1, final concentration 40 pM) (iv) Binding buffer (125 pl) Each plate was sealed with plate sealer from PACKARD and incubated overnight with rocking at 4°C 4. Plates were counted using PACKARD TOPCOUNT inhibition was calculated as follows: A total counts B nonspecific counts C sample counts inhibition x 100 -51- WO 98/31359 PCT/US98/00617 OCFORM ASSAY Osteoblast-like cells (1.8 cells), originally derived from mouse calvaria, were plated in CORNING 24 well tissue culture plates in a MEM medium containing ribo- and deoxyribonucleosides, 10% fetal bovine serum and penicillin-streptomycin. Cells were seeded at 40,000/well in the morning. In the afternoon, bone marrow cells were prepared from six week old male Balb/C mice as follows: Mice were sacrificed, tibiae removed and placed in the above medium. The ends were cut off and the marrow was flushed out of the cavity into a tube with a 1 mL syringe with a 27.5 gauge needle.

The marrow was suspended by pipetting up and down. The suspension was passed through >100 pm nylon cell strainer. The resulting suspension was centrifuged at 350 x g for seven minutes. The pellet was resuspended, and a sample was diluted in 2% acetic acid to lyse the red cells. The remaining cells were counted in a hemacytometer. The cells were pelleted and resuspended at 1 x 106 cells/mL. 50 gL was added to each well of 1.8 cells to yield 50,000 cells/well and 1,25-dihydroxy-vitamin D3(D3) was added to each well to a final concentration of 10 nM. The cultures were incubated at 37 0 C in a humidified, 5% CO2 atmosphere.

After 48 h, the medium was changed. 72 h after the addition of bone marrow, test compounds were added with fresh medium containing D3 to quadruplicate wells. Compounds were added again after 48 h with fresh medium containing D3. After an additional 48 h the medium was removed, cells were fixed with 10% formaldehyde in phosphate buffered saline for 10 minutes at room temperature, followed by a 1-2 minute treatment with ethanol:acetone and air dried. The cells were then stained for tartrate resistant acid phosphatase as follows: The cells were stained for 10-15 minutes at room temperature with 50 mM acetate buffer, pH 5.0 containing 30 mM sodium tartrate, 0.3 mg/mL Fast Red Violet LB Salt and 0.1 mg/mL Naphthol AS -MX phosphate. After staining, the plates were washed extensively with deionized water and air dried. The number of multinucleated, positive staining cells were counted in each well.

-52- WO 98/31359 PCT/US98/00617 EXAMPLE OF A PHARMACEUTICAL FORMULATION As a specific embodiment of an oral composition, 100 mg of compound 1 (shown in Table 1) is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.

While the invention has been described and illustrated in reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred doses as set forth hereinabove may be applicable as a consequence of variations in the responsiveness of the mammal being treated for severity of bone disorders caused by resorption, or for other indications for the compounds of the invention indicated above.

Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be limited only by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

-53-

Claims (32)

1. A compound of the formula X-Y-Z-Aryl-A-B wherein Aryl is a 6-membered aromatic ring containing 0, 1 or 2 nitrogen atoms wherein Aryl is unsubstituted or substituted with R 8 and R 9 X is selected from 1 23 3 4 -NR R, -C-NR R, -NR -C-NR R, a 5- or 6- membered monocyclic aromatic or nonaromatic ring system containing 0, 1 or 2 heteroatoms selected from N, 0 or S wherein the 5- or 6-membered ring system is either unsubstituted or substituted with R' and R 2 or a 9- to 14-membered fuised polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1, 2 or 3 heteroatoms selected from N, 0 or S, and wherein the polycyclic ring system is either unsubstituted or substituted with R' and R 2 Y is selected from the group consisting of 20 Co. 8 alkylene, C 3 10 cycloalkyl, C 0 5 alkylene-NR O-CO-CO 0 4 alkylene, C 04 8 alkylene-CONR'-CO.. 8 alkylene, CO 4 8 alkylene-O-CO.. 8 alkylene, CO 0 8 allcylene-NRI 0 -CO.. 8 alkylene, C 04 8 alkylene-S(O)0. 2 -CO.. 8 alkylene, CO.. 8 alkylene-S0 2 -NR 0 -C 0 8 alkylene, C 04 8 alkylene-NR 10 -S0 2 -CO..s alkylene, C 04 8 alkylene-CO-CO- 8 alkylene, (CH 2 )0o 6 aryl(CH 2 )0o 6 (CH 2 )0o 6 aryl-CO-(CH 2 )o- 6 (CH 2 )o- 6 aryl-CO-NI{-(CH 2 )0o 6 or OR, (C;H 2 8 CH(CH 2 0 8 Z and A are each independently selected from

011- -IPS(CH 2 (CH 2 )mO(CFI 2 (CH 2 )mNR 1 (CH 2 )n, [I:\DAYLIB\ibaa18429.doc:kww 0 0 0 (CH 2 )mCNRii1 (0H 2 )n,(0H 2 )m NR 1 1 C(CHM 2 )n,(CH 2 )mC(CH 2 )n, S 0 (CH 2 )mC(CH 2 (0H 2 )mSO 2 (CH 2 (0H 2 )mS(0H 2 )n, (CH 2 )mSO(CH 2 (CH 2 )mSO 2 NR 1 l(CH 2 (CH 2 )mNRI 1 SO 2 (CH 2 (CH 2 )mCR 11 =CR 12 (CH 2 or (CH 2 )mC=C(C 2 n where m and n are each independently an integer from 0 to 4; B is 0 11 13 C-R 6R 7 where p is an integer from 1 to 3; R 2 R 3 R 4 R 5 R 8 R, R1 1 and R 1 2 are each independently selected from hydrogen, halogen, CI 1 1 0 alkyl, aryl C 0 8 alkyl, .00 15 amino CO 0 8 alkyl, C 1 3 acylamino CO 0 8 alkyl, CI. 6 alkylamino CO 0 8 alkyl, 00 C 1 6 dialkylamino CO 0 8 alkyl, 0: aryl C 0 6 alkylamino C 0 6 alkyl, C14 alkoxyamino CO 0 8 alkyl, hydroxy CI- 6 alkylamino CO.. 8 alkyl, CI4 alkoxy CO 0 6 alkyl, or C14 alkoxycarbonyl C 0 6 alkyl; R 6is selected from hydrogen, ~C C 1 8 alkyl or aryl CO.. 6 alkyl; [1:\DAYLIB\Iibaa]8429.doc:kww *R 7 is selected from C 7 1 5 polycyclyl C 0 6 alkylsulfonylamino C 0 6 alkyl or C 7 1 5 polycyclyl C 0 6 alkylcarbonylamino C 0 6 alkyl; wherein the polycyclyl may be unsubstituted or substituted with R 14 R 15, R 16and R1 7 and wherein any of the alkyl groups may be unsubstituted or substituted with R 14 and R1 5 *R1 3 is selected from hydroxy, C 1 8 alkyloxy, aryl C 0 6 alkyloxy, C 1 8 alkylcarbonyloxy C1A4 alkyloxy, aryl C 1 8 alkylcarbonyloxy CI14 alkyloxy, C1 -6 dialkylamninocarbonylmethyloxy, aryl C 1 6 dialkylaminocarbonylmethyloxy or an L- or D-amino acid joined by an amide linkage and wherein the carboxylic acid moiety of said amino acid is as the free acid or is esterified by C 1 6 alkyl; and R 14 R' 5 R 1 and R' are each independently selected from hydrogen, halogen, 20 C 1 10 alkyl, C 3 8 cycloalkyl, oxo, aryl, aryl C 1 8 alkyl, amino, amino C 1 8 alkyl, 1 3 acylamnino, C 1 3 acylamino C 1 8 alkyl, C 1 6 alkylamino, C 1 6 alkylamino-C.. 8 000* alkyl, C 1 6 dialkylamnino, C 1 6 dialkylamino C 1 8 alkyl, CI-4 alkoxy, CIA4 alkoxy- C 1 6 alkyl, hydroxycarbonyl, hydroxycarbonyl C 1 6 alkyl, C 1 3 alkoxycarbonyl, C 1 3 alkoxycarbonyl C 1 6 alkyl, hydroxycarbonyl-C.. 6 alkyloxy, hydroxy, hydroxy C 1 6 alkyl, C 1 6 alkyloxy C 1 6 alkyl, nitro, cyano, trifluoromethyl, 25 trifluoromethoxy, trifluoroethoxy, 1I-8 alkyl-S(O)q, 1..8 alkylaminocarbonyl, C 1 8 dialkylaminocarbonyl, 1-8 alkyloxycarbonylamino, 1..8 alkylaminocarbonyloxy or 1I-8 alkylsulfonylamino; and the pharmaceutically acceptable salts thereof, provided that R 7 is not camphosulfonylamino. 2. The compound of claim 1, wherein Aryl is a phenyl or pyridyl ring which is unsubstituted or substituted with R 8 X is a 9- to 14-membered fused polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1. 2 or 3 [I:\DAYLIB\Iibaa]8429.doc:kww 57 heteroatoms selected from N, 0 or S, and wherein the polycyclic ring system is either unsubstituted or substituted with R' and R; Y is selected from CO.. 6 alkylene, C 0 6 alkylene-NR 0 -CO-CO. 6 alkylene, CO. 6 alkylene-CONR' 0 -CO. 6 alkylene, C 0 6 alkylene-0-CO 0 6 alkylene, CO..6 alkylene-NR' 0 -Co-6 alkylene, C 0 6 alkylene-S(O)0o 2 -CO- 6 alkylene, C 0 6 alkylene-S0 2 -NRI 0 -CO.. 6 alkylene, or CO.. 6 alkylene-aryl-C.. 6 alkylene; Z is selected from 0 111 (CH 2 (CH 2 )mO(CH 2 )n or (0H 2 )mNR 11 C(CH 2 )n; A is 0 Bs(C;H 2 )mC;NR C(CH 2 )n; B is 13 R6R R,RR,R,R, R and R 12are each independently selected from hydrogen, halogen, C 1 1 o alkyl, aryl CO.. 8 alkyl, C14 alkoxy C 0 -6 alkyl, or C14 alkoxycarbonyl CO-6 alkyl; *R 6 is hydrogen; *R 7 is selected from C 7 1 0 polycyclyl CO. 6 alkcylsulfonylamino CO.. 6 alkyl or C 7 1 0 polycyclyl CO. 6 alkylcarbonylamino CO.. 6 alkyl; [I:\DAYLIB\Iiba]8429.doc:kWW 58 14 wherein the polycyclyl may be unsubstituted or substituted with R R 15,R 16and R 17 *R1 3 isselected from hydroxy or C 1 I.-g alkyloxy; *R1 4 R1 5 R 16 and R 1 7 are each independently selected from hydrogen, halogen, C 1 6 alkyl, C 3 7 cycloalkyl, oxo, amino, amino CI.. 8 alkyl, C 1 3 acylamino, C 1 3 acylamnino, C 1 8 alkyl, C 1 6 alkylamino, C 1 6 alkylamino C 1 8 alkyl, C 1 6 dialkylamino, C 1 6 dialkylamino C 1 8 alkyl, C 1 4 alkoxy, C14 alkoxy C 1 6 alkyl, hydroxycarbonyl, hydroxycarbonyl C 1 6 alkyl, C 1 3 alkoxycarbonyl, C 1 3 alkoxycarbonyl C 1 6 alkyl, hydroxycarbonyl C 1 6 alkyloxy, hydroxy, hydroxy C 1 6 alkyl, C 1 6 alkyloxy C 1 6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, C 1 alkylsulfonyl, C 1 8 alkylamninocarbonyl, C 1 -8 alkyloxycarbonylamino, C 1 8 alkylaminocarbonyloxy or C 1 -8 alkylsulfonylamino; and the pharmaceutically acceptable salts thereof; provided that R 7 is not camphorsulfonylamino. The compound of Claim 2, of the formula: .8 0 0 X-Y- R 13 wherein X is selected from the group consisting of N N R 2 R R 2 R HN NN N N N H H H Y is selected from C 0 6 alkylene, C 0 6 alkylene-O-CO.. 6 alkylene or C 0 6 alkylene-NR 10 -CO-6 alkylene; Z is selected from (CH 2 )m or (CH 2 )m0O(CH 2 )n; R R 14 R 15 R 16 and R 1 7 are each independently selected from [I:\DAYLIB\IibaaS429dOC:kWW 59 hydrogen, halogen, C 1 -6 alkyl, oxo, or hydroxy; and the pharmaceutically acceptable salts thereof; provided that R 7 is not camphorsulfonylamino. 4. The compound of Claim 2, of the formula: R o X-Y-Z N R 13 H N-S02-(CH 2 )q-R 8 H wherein q is an integer from 0 to 2; R 1 8 is selected from 0 or and the pharmaceutically acceptable salts thereof; provided that when q is 1, R' 8 is not 0 5. The compound of Claim 4, selected from O 2 C O 2 H H H' N 02 15 or .C0 2 H [I:\DAYLIB\Iibaa]8429.dmc:kw and the pharmaceutically acceptable salts thereof. 6. An avp3 antagonist, av35 antagonist or dual avp3/av5 antagonist compound, substantially as hereinbefore described with reference to any one of the examples. 7. A process of preparing an cav3 antagonist, avp5 antagonist or dual antagonist compound, the process being substantially according to the procedure of any one of the schemes or examples as hereinbefore disclosed. 8. An avp3 antagonist, av35 antagonist or dual avp3/av5 antagonist compound prepared by the process of claim 7. 9. A pharmaceutical composition comprising a compound of any one of claims 1 to 6 or 8, and a pharmaceutically acceptable carrier. A composition of claim 9, which further comprises an active ingredient selected from the group consisting of an organic bisphosphonate or a pharmaceutically-acceptable salt or ester thereof, an oestrogen receptor modulator, and a cytotoxic/antiproliferative agent, and mixtures thereof. 11. A composition of claim 10, wherein said organic bisphosphonate or pharmaceutically-acceptable salt or ester thereof is alendronate monosodium trihydrate. S12. A pharmaceutical composition made by combining a compound of any one of claims 1 to 6 or 8, and a pharmaceutically acceptable carrier. 20 13. A process for making a pharmaceutical composition comprising combining a compound of any one of claims 1 to 6 or 8, and a pharmaceutically acceptable carrier.

14. A method of eliciting a vitronectin antagonising effect in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a *4•4 25 compound of any one of claims 1 to 6 or 8, or of a composition of any one of claims 9 to 12. A compound of any one of claims 1 to 6 or 8 or a composition of any one of claims 9 to 12 when used in eliciting a vitronectin antagonising effect in a mammal.

16. A compound of any one of claims 1 to 6 or 8 or a composition of any one of claims 9 to 12 for use in eliciting a vitronectin antagonising effect in a mammal.

17. The use of a compound of any one of claims 1 to 6 or 8 for the manufacture of a medicament for eliciting a vitronectin antagonising effect in a mammal.

18. The method of claim 14, wherein the vitronectin antagonising effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of [I:DAYLB\ibaa]8429.doc:kw 61 angiogenesis, inhibition of atherosclerosis, inhibition of inflammation, inhibition of viral disease, inhibition of diabetic retinopathy, inhibition of macular degeneration or inhibition of tumour growth.

19. The method of claim 18, wherein the vitronectin antagonising effect is the inhibition of tumour growth. A compound or composition of claim 15 or claim 16, wherein the vitronectin antagonising effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of angiogenesis, inhibition of atherosclerosis, inhibition of inflammation, inhibition of viral disease, inhibition of diabetic retinopathy, inhibition of to macular degeneration or inhibition of tumour growth.

21. A compound or composition of claim 20 wherein the vitronectin antagonising effect is the inhibitor of tumour growth.

22. A use of claim 17, wherein the vitronectin antagonising effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of angiogenesis, inhibition of atherosclerosis, inhibition of inflammation, inhibition of viral disease, inhibition of diabetic retinopathy, inhibition of macular degeneration or inhibition of tumour growth. 0 r

23. The use of claim 22 wherein the vitronectin antagonising effect is the *o inhibition of tumour growth. 400 20 24. A method of treating or preventing a condition mediated by antagonism of a vitronectin receptor in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1 to 6 or 8, or of a composition of any one of claims 9 to 12.

25. A compound of any one of claims 1 to 6 or 8 or a composition of any 25 one of claims 9 to 12 when used in treating or preventing a condition mediated by antagonism of a vitronectin receptor in a mammal.

26. A compound of any one of claims 1 to 6 or 8 or a composition of any one of claims 9 to 12 for use in treating or preventing a condition mediated by antagonism of a vitronectin receptor in a mammal.

27. The use of a compound of any one of claims 1 to 6 or 8 for the manufacture of a medicament for treating or preventing a condition mediated by antagonism of a vitronectin receptor in a mammal.

28. The method of claim 24, wherein the condition is selected from the group consisting of osteoporosis and cancer. [:ADAYLIB\ibaa]8429.doc:k w 62

29. A compound or composition of claim 25 or claim 26, wherein the condition is selected from the group consisting of osteoporosis and cancer. The use of claim 27, wherein the condition is selected from the group consisting of osteoporosis and cancer.

31. A method of inhibiting tumour growth in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1 to 6 or 8, or of a composition of any one of claims 9 to 12.

32. A compound of any one of claims 1 to 6 or 8 or a composition of any one of claims 9 to 12 when used in inhibiting tumour growth in a mammal. S 0 0 0 0 S. I 0 S. S 0 S S 0S 0 0 one of cl manufac administ compou 20 conjunct administ one of cl 25 one of cl one of cl manufac administ

33. A compound of any one of claims 1 to 6 or 8 or a composition of any aims 9 to 12 for use in inhibiting tumour growth in a mammal.

34. The use of a compound of any one of claims 1 to 6 or 8 for the ture of a medicament for inhibiting tumour growth in a mammal.

35. The method of claim 31, wherein said compound or composition is ered in conjunction with radiation therapy.

36. A compound or composition of claim 32 or claim 33, wherein said nd or composition is administered in conjunction with radiation therapy.

37. The use of claim 34, wherein said medicament is administered in ion with radiation therapy.

38. A method of treating cancer in a mammal, the method comprising ering to the mammal a therapeutically effective anjount of a compound of any aims 1 to 6 or 8, or of a composition of any one of claims 9 to 12.

39. A compound of any one of claims 1 to 6 or 8 or a composition of any aims 9 to 12 when used in treating cancer in a mammal.

40. A compound of any one of claims 1 to 6 or 8 or a composition of any aims 9 to 12 for use in treating cancer in a mammal.

41. The use of a compound of any one of claims 1 to 6 or 8 for the ture of a medicament for treating cancer in a mammal.

42. A method of treating cancer in a mammal, the method comprising ering to the mammal a therapeutically effective amount of a compound of any one of claims 1 to 6 or 8 and of one or more agents known to be cytotoxic or antiproliferative, or of a composition of claim [I:\DAYLIB\Iibaa]8429.do:k 63

43. A compound of any one of claims 1 to 6 or 8 and one or more agents known to be cytotoxic or antiproliferative or a composition of claim 10 when used in treating cancer in a mammal.

44. A compound of any one of claims 1 to 8 and one or more agents known to be cytotoxic or antiproliferative or a composition of claim 10 for use in treating cancer in a mammal. The use of a compound of any one of claims 1 to 6 or 8 and one or more agents known to be cytotoxic or antiproliferative for the manufacture of a medicament for treating cancer in a mammal.

46. A method of treating cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1 to 6 or 8 or of a composition of any one of claims 9 to 12, and of a VEGF inhibitor compound.

47. A compound of any one of claims 1 to 6 or 8 or a composition of any one of claims 9 to 12, and a VEGF inhibitor compound when used in treating cancer in a mammal. *48. A compound of any one of claims 1 to 6 or 8 or a composition of any one of claims 9 to 12, and a VEGF inhibitor compound for use in treating cancer in a mammal. 20 49. The use of a compound of any one of claims 1 to 6 or 8 and a VEGF inhibitor compound for the manufacture of a medicament for treating cancer in a mammal. The method of claim 46, which further comprises treating a condition S* selected from cancer, macular degeneration, or diabetic retinopathy. 0 25 51. A compound or composition of claim 47 or claim 48, which further comprises treating a condition selected from cancer, macular degeneration, or diabetic retinopathy.

52. The use of claim 49 which further comprises treating a condition selected from cancer, macular degeneration, or diabetic retinopathy. Dated 30 November, 2000 Merck Co., Inc. Patent Attorneys for the Applicant/Nominated Person f SPRUSON FERGUSON [I:\DAYLB\ibaa]8429dC:k W